Myriad Genetics, Inc. (MYGN) Tops Q1 EPS by 1c, Reaffirms FY12 Guidance
Tweet
Share
E-mailGet Alerts MYGN Hot Sheet
Price: $3.42 +1.79%
Financial Fact:
Research and development expense: 19.4M
Today's EPS Names:
ANAB, ANIX, MNY, More
Financial Fact:
Research and development expense: 19.4M
Today's EPS Names:
ANAB, ANIX, MNY, More
Join SI Premium – FREE
Myriad Genetics, Inc. (NASDAQ: MYGN) reported Q1 EPS of $0.29, $0.01 better than the analyst estimate of $0.28. Revenue for the quarter came in at $110.5 million versus the consensus estimate of $106.49 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Assumes Myriad Genetics (MYGN) at Neutral
- Core & Main, Inc (CNM) Tops Q3 EPS by 2c ; Offers Guidance
- Macy's (M) Tops Q2 EPS by 28c, Beats on Revenue; Offers FY Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
